Second-Line Treatment for Cholangiocarcinoma

Guideline-Based Recommendations

• The European Association for the Study of the Liver (EASL) acknowledges irinotecan-based options only as alternatives to FOLFOX based on phase II trial data, not as preferred therapy 3, 4
• The French Association for the Study of the Liver (AFEF) explicitly states that there is not enough data to support the place of irinotecan alone or in combination with fluoropyrimidines as a standard of care in second line in European patients 1, 2

Evidence for Irinotecan-Based Combinations

• The NIFTY trial showed improved overall survival with nanoliposomal irinotecan plus fluorouracil/leucovorin versus fluorouracil alone (8.6 vs 5.3 months; HR 0.68) 3, 4
• The American College of Gastroenterology recommends FOLFOX as the established standard of care for second-line treatment in cholangiocarcinoma after progression on gemcitabine plus cisplatin, based on the randomized phase III ABC-06 trial 1, 2, 3, 4

Clinical Algorithm for Second-Line Treatment

• The National Comprehensive Cancer Network (NCCN) recommends performing comprehensive molecular profiling to identify actionable alterations (FGFR2, IDH1, BRAF, HER2, MSI, NTRK) 1, 2, 3, 4
• The European Society for Medical Oncology (ESMO) suggests that FOLFOX remains the recommended second-line chemotherapy for patients with good performance status (ECOG 0-1) 1, 2, 3, 4

Quality of Life Considerations

• The American Society of Clinical Oncology (ASCO) notes that the modest survival benefit of any second-line therapy must be weighed against treatment-related toxicity 1, 2, 3